DIATHEVA is an Italian biotech company founded in 2002 with the aim to bring research into industrial products by cooperating with firms, public and private research institutions.
DIATHEVA focuses on development, production and marketing of new and innovative products (antibodies, recombinant proteins, immunoassays and SNPs detection kits) for diagnostics, research and therapeutic applications in the field of: Cancer, Microbial Infection and Pharmacogenetics.
DIATHEVA has a GMP authorized facility designed for the manufacture of APIs for pre-clinical and clinical trial studies with a special emphasis on new immunogens against HIV and other microbial pathogens
Diatheva’s pipeline antibody-based therapies is designated to address significant unmet medical needs and by its productive technology suite capable of selecting, manufacturing in GMP compliance and characterizing innovative next generation...Read more
Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer LEXINGTON, MA -- July 20, 2015 -- Agenus Inc. (NASDAQ: AGEN), an immunology company...Read more